64 studies found for:    IL2RA
Show Display Options
Rank Status Study
1 Unknown  Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation
Conditions: Kidney Transplantation;   Kidney Diseases;   Kidney Failure
Interventions: Drug: Alemtuzumab;   Drug: Daclizumab
2 Completed Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX
Condition: Liver Transplantation
Interventions: Drug: tacrolimus;   Drug: Anti-IL2R AB;   Drug: Mycophenolate mofetil;   Drug: prednisone
3 Completed Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients
Conditions: Hepatitis C;   Liver Transplantation
Interventions: Drug: Tacrolimus;   Drug: steroids, monoclonal anti-IL2R antibody
4 Active, not recruiting Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
Condition: End Stage Renal Disease
Interventions: Drug: Rabbit Antithymocyte globulin;   Drug: Daclizumab
5 Completed Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.
Condition: Liver Transplantation
Intervention: Drug: tacrolimus
6 Completed A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Daclizumab
7 Completed Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
Condition: Renal Transplantation
Intervention:
8 Not yet recruiting Preemptive Therapy of GVHD
Condition: Graft-vs-host Disease
Intervention: Drug: rabbit antithymocyte globulin
9 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
10 Completed ANTI-TAC THERAPY FOR UVEITIS
Condition: Uveitis
Intervention: Drug: Daclizumab (Zenapax)
11 Completed
Has Results
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Methotrexate;   Drug: Placebo
12 Completed
Has Results
Abatacept With Methotrexate- Phase IIB
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept (BMS-188667);   Drug: Placebo
13 Completed
Has Results
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Placebo
14 Completed Zenapax to Treat Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Zenapax
15 Completed Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
Condition: Leukemia, T-Cell
Intervention: Drug: Humanized MiK-Beta-1 Monoclonal Antibody (Anti-CD122)
16 Completed Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Condition: Renal Transplantation
Interventions: Drug: Thymoglobulin (ATG);   Drug: Daclizumab
17 Completed Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
Condition: Renal Transplant Rejection
Interventions: Procedure: Kidney transplantation with MSCs infusion;   Procedure: kidney transplantation without MSC infusion
18 Unknown  A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
Conditions: Aplastic Anemia;   Pure Red Cell Aplasia;   Diamond Blackfan Anemia
Interventions: Drug: Daclizumab;   Drug: Daclizumab (Zenapax)
19 Completed
Has Results
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Conditions: Graft vs Host Disease;   Myelodysplastic Syndromes;   Leukemia;   Leukemia, Myeloid;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Lymphocytic;   Lymphoma;   Lymphoma, Mantle-cell;   Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Drug: RFT5-SMPT-dgA;   Drug: Nexell Isolex system
20 Completed
Has Results
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Condition: Leukemia, Adult T-Cell
Intervention: Biological: Denileukin diftitox (Ontak)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years